Skip to main content
. Author manuscript; available in PMC: 2015 Jun 7.
Published in final edited form as: Cancer. 2010 Oct 1;116(19):4580–4589. doi: 10.1002/cncr.25319

Figure 2.

Figure 2

Overall survival by therapy (modified fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone [hyper-CVAD] vs standard hyper-CVAD) is shown within the (Top) CD20-negative and (Bottom) CD20-positive subsets.